Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | FADS1 | O60427 | 2/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370993 | 0.98 | MAP1LC3B (0.39) | MAP1LC3BMAOBTDP1FADS1ALPL | |
| SCHEMBL12371032 | 0.90 | NOTUM (0.38) | NOTUM | |
| SCHEMBL12371016 | 0.85 | TNKS (0.37) | MAOBTDP1NOTUM | |
| SCHEMBL12370942 | 0.84 | SLC2A1 (0.41) | MAP1LC3B | |
| SCHEMBL2273765 | 0.84 | MAP1LC3B (0.39) | MAP1LC3BMAOB | |
| SCHEMBL2271030 | 0.84 | MAP1LC3B (0.39) | MAP1LC3BMAOB | |
| SCHEMBL2271037 | 0.84 | MAP1LC3B (0.39) | MAP1LC3BMAOB | |
| SCHEMBL2271032 | 0.84 | MAP1LC3B (0.39) | MAP1LC3BMAOB | |
| SCHEMBL2273714 | 0.84 | MAP1LC3B (0.39) | MAP1LC3BMAOB | |
| SCHEMBL12370948 | 0.83 | USP5 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | OGDH, OXGR1, OXER1 | MAP1LC3B 3038/4885MAOB 184/4885TDP1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.